ArticleFrontiers in pharmacology2019
Synergistic Combination of Polymyxin B and Enrofloxacin Induced Metabolic Perturbations in Extensive Drug-Resistant
Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Development of polymyxin- and aminoglycoside-based outer membrane permeabilizers: a review.Frontiers in microbiology · 2025Review
- Synergistic Activity and Mechanism of Sanguinarine with Polymyxin B against Gram-Negative Bacterial Infections.Pharmaceutics · 2024Article
- Resensitizing multidrug-resistant Gram-negative bacteria to carbapenems and colistin using disulfiram.Communications biology · 2023Article
- Modulation ofBiomedicines · 2023Article
- The Impact of the Virulence ofVeterinary sciences · 2023Article
- Drug Combination of Ciprofloxacin and Polymyxin B for the Treatment of Multidrug-ResistantPharmaceutics · 2023Article
- Metabolic perturbations and key pathways associated with the bacteriostatic activity ofAccess microbiology · 2023Article
- Isotopic Tracer for Absolute Quantification of Metabolites of the Pentose Phosphate Pathway in Bacteria.Metabolites · 2022Review
- Integrated metabolomic and transcriptomic analyses of the synergistic effect of polymyxin-rifampicin combination against Pseudomonas aeruginosa.Journal of biomedical science · 2022Article
- In Vitro Activity of Robenidine Analogues NCL259 and NCL265 against Gram-Negative Pathogens.Antibiotics (Basel, Switzerland) · 2022Article
- Antimicrobial Susceptibility of Bacterial Isolates from Donkey Uterine Infections, 2018-2021.Veterinary sciences · 2022Article
- Rescuing the Last-Line Polymyxins: Achievements and Challenges.Pharmacological reviews · 2021Review
- Polymyxins, the last-resort antibiotics: Mode of action, resistance emergence, and potential solutions.Journal of biosciences · 2021Review
- A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections.Frontiers in medicine · 2021Article
- Metabolomic Description of Ivacaftor Elevating Polymyxin B Mediated Antibacterial Activity in Cystic FibrosisACS pharmacology & translational science · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymyxins are used as a last-resort class of antibiotics against multidrug-resistant (MDR) Gram-negative
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.